iCrowd Newswire – Jul 1, 2020
Global hospital-acquired infection diagnostics market attained a value of $2,657.6 million and is expected to reach a value of $4,386.6 million by 2023, progressing at a 7.6% CAGR during the forecast period (2017–2023), according to the latest research study published by P&S Intelligence, the study covers detailed analysis of component and distribution channel of hospital-acquired infection diagnostics industry.
While some advances have been made when it comes to controlling infections spreading in hospitals, advancements in therapeutics and biomedical technology are further producing larger number of highly susceptible patients . Ascribed to this, the need for HAI diagnostics is increasing rapidly. The products used for diagnosing HAIs are instruments and reagents & consumables, between which, the demand for reagents & consumable was higher due to the expansion in the molecular diagnostic testing volumes.
Request to view sample of this market research: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample
Different HAI infection types are hospital acquired pneumonia, gastrointestinal infections, urinary tract infections (UTI), bloodstream infections, and surgical site infections. In 2017, hospital acquired UTIs were caused the most. This infection is generally caused because of medical devices such as due to the improper utilization of catheters. As per the Centers for Disease Control and Prevention, 75% hospital acquired UTIs are associated with urinary catheters. In addition to this, the prevalence of hospital acquired gastrointestinal infections is also projected to increase in the coming years.
The objective of this research includes;
- Market restraints and their impact during the short, medium, and long terms
- Recent trends and evolving opportunities for the HAI diagnostics market participants
- Historical and the present size of the market segments and understand their comparative future potential
- Potential of on-demand logistics services, so the HAI diagnostics market players make informed decisions on the sales of their offerings
- Competitive scenario of various market segments across key countries in several regions for uncovering market opportunities for the stakeholders
The HAI diagnostics market in North America was the highest contributor accounting for $1,022.9 million in 2016, attributed to the increase in geriatric population. Adoption of advance HAI diagnostics techniques for disease diagnosis also provides opportunity for the growth of the market in North America.
Some of the other key players operating in the HAI diagnostics market are AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.
The research includes detailed analysis of;
- Reagents & Consumables
- Molecular Diagnostics
- Drug-resistance Testing
- Disease Testing
- Urinary Tract Infections (UTIs)
- Surgical Site Infections
- Bloodstream Infections
- Gastrointestinal Infections
- Hospital Acquired Pneumonia
- Ambulatory Surgery Centers (ASCs)
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Email: [email protected]
Keywords: Hospital-Acquired Infection Diagnostics Market, Size, Share, Demand